BioCentury | May 12, 2014
Company News

Pantec, Takeda deal

...will use Pantec's Precise Laser EpidermAl SystEm (PLEASE) Professional laser device with topical drug formulations. Pantec...
...active drug in the formulations, but the formulations will be developed by Pantec's undisclosed partners. Pantec...
...be responsible for funding. Pantec said the trial will "most likely" start in early 2015. Pantec...
BioCentury | Nov 21, 2011
Company News

Pantec sales and marketing update

...laser device worldwide for transdermal drug delivery of large molecular weight drugs and aesthetic dermatology. Pantec Biosolutions AG...
BioCentury | Feb 21, 2011
Company News

Catalent Pharma, Pantec deal

...Catalent received exclusive, worldwide rights to Pantec's Lyopan technology. Lyopan is used to manufacture active pharmaceutical...
...and OTC products. Further terms were not disclosed. Catalent Pharma Solutions Inc. , Somerset, N.J. Pantec Biosolutions AG...
BioCentury | Jul 26, 2010
Financial News

Pantec completes venture financing

Pantec Biosolutions AG , Ruggell, Liechtenstein Business: Drug delivery Date completed: 7/20/10 Type: Venture financing Raised: CHF20 million ($19.1 million) Investor: StemCell Holding AG Note: The offering comprises two financing rounds. Further terms were not disclosed....
BioCentury | Jul 26, 2010
Company News

Pantec board of directors update

Pantec Biosolutions AG , Ruggell, Liechtenstein Business: Drug delivery Appointed: Manfred Asamer, CEO of Asamer Holding AG; and Werner Lanthaler, CEO of Evotec AG WIR Staff...
BioCentury | Jul 21, 2010
Financial News

Pantec raises $19.1 million

...CHF20 million ($19.1 million) through two undisclosed financing rounds led by new investor StemCell Holding. Pantec...
...CEO of Asamer Holding AG; and Werner Lanthaler, CEO of Evotec AG (Xetra:EVT), will join Pantec's...
BioCentury | Jun 7, 2010
Clinical News

PLEASE transdermal delivery device regulatory update

...deliver biologics or small molecules using intraepidermal microporation for dermatology and in general medicine applications. Pantec...
...said an in vitro fertilization hormone therapy product using the device is in clinical testing. Pantec Biosolutions AG...
BioCentury | Mar 1, 2010
Clinical News

P: Phase I data

...Data from a Phase I trial in 6 healthy male volunteers showed that treatment with Pantec's...
...hormone (FSH) patch achieved reproducible pharmacokinetics with negligible inter-subject variability. There were no adverse events. Pantec Biosolutions AG...
BioCentury | Apr 27, 2009
Clinical News

P: Phase I data

...a German, pilot Phase I trial in 6 healthy male volunteers showed that treatment with Pantec's...
...of adverse events and the P.L.E.A.S.E.-triptorelin patch combination produced reproducible pharmacokinetics with little inter-individual variability. Pantec Biosolutions AG...
BioCentury | May 19, 2008
Company News

Pantec board of directors update

Pantec Biosolutions AG , Ruggell, Liechtenstein Business: Drug delivery Appointed: Burkhard Feurstein, director of finance at Gamma Capital Partners AG; Michael Armbruester, founder of JB Commodities WIR Staff...
Items per page:
1 - 10 of 10
BioCentury | May 12, 2014
Company News

Pantec, Takeda deal

...will use Pantec's Precise Laser EpidermAl SystEm (PLEASE) Professional laser device with topical drug formulations. Pantec...
...active drug in the formulations, but the formulations will be developed by Pantec's undisclosed partners. Pantec...
...be responsible for funding. Pantec said the trial will "most likely" start in early 2015. Pantec...
BioCentury | Nov 21, 2011
Company News

Pantec sales and marketing update

...laser device worldwide for transdermal drug delivery of large molecular weight drugs and aesthetic dermatology. Pantec Biosolutions AG...
BioCentury | Feb 21, 2011
Company News

Catalent Pharma, Pantec deal

...Catalent received exclusive, worldwide rights to Pantec's Lyopan technology. Lyopan is used to manufacture active pharmaceutical...
...and OTC products. Further terms were not disclosed. Catalent Pharma Solutions Inc. , Somerset, N.J. Pantec Biosolutions AG...
BioCentury | Jul 26, 2010
Financial News

Pantec completes venture financing

Pantec Biosolutions AG , Ruggell, Liechtenstein Business: Drug delivery Date completed: 7/20/10 Type: Venture financing Raised: CHF20 million ($19.1 million) Investor: StemCell Holding AG Note: The offering comprises two financing rounds. Further terms were not disclosed....
BioCentury | Jul 26, 2010
Company News

Pantec board of directors update

Pantec Biosolutions AG , Ruggell, Liechtenstein Business: Drug delivery Appointed: Manfred Asamer, CEO of Asamer Holding AG; and Werner Lanthaler, CEO of Evotec AG WIR Staff...
BioCentury | Jul 21, 2010
Financial News

Pantec raises $19.1 million

...CHF20 million ($19.1 million) through two undisclosed financing rounds led by new investor StemCell Holding. Pantec...
...CEO of Asamer Holding AG; and Werner Lanthaler, CEO of Evotec AG (Xetra:EVT), will join Pantec's...
BioCentury | Jun 7, 2010
Clinical News

PLEASE transdermal delivery device regulatory update

...deliver biologics or small molecules using intraepidermal microporation for dermatology and in general medicine applications. Pantec...
...said an in vitro fertilization hormone therapy product using the device is in clinical testing. Pantec Biosolutions AG...
BioCentury | Mar 1, 2010
Clinical News

P: Phase I data

...Data from a Phase I trial in 6 healthy male volunteers showed that treatment with Pantec's...
...hormone (FSH) patch achieved reproducible pharmacokinetics with negligible inter-subject variability. There were no adverse events. Pantec Biosolutions AG...
BioCentury | Apr 27, 2009
Clinical News

P: Phase I data

...a German, pilot Phase I trial in 6 healthy male volunteers showed that treatment with Pantec's...
...of adverse events and the P.L.E.A.S.E.-triptorelin patch combination produced reproducible pharmacokinetics with little inter-individual variability. Pantec Biosolutions AG...
BioCentury | May 19, 2008
Company News

Pantec board of directors update

Pantec Biosolutions AG , Ruggell, Liechtenstein Business: Drug delivery Appointed: Burkhard Feurstein, director of finance at Gamma Capital Partners AG; Michael Armbruester, founder of JB Commodities WIR Staff...
Items per page:
1 - 10 of 10